OBJECTIVE： To identify global research trends of stem cell transplantation for treating Parkinson＇s disease using a bibliometric analysis of the Web of Science. DATA RETRIEVAL： We performed a bibliometric analysis ...OBJECTIVE： To identify global research trends of stem cell transplantation for treating Parkinson＇s disease using a bibliometric analysis of the Web of Science. DATA RETRIEVAL： We performed a bibliometric analysis of data retrievals for stem cell transplantation for treating Parkinson＇s disease from 2002 to 2011 using the Web of Science. SELECTION CRITERIA： Inclusion criteria： （a） peer-reviewed articles on stem cell transplantation for treating Parkinson＇s disease which were published and indexed in the Web of Science; （b） type of articles： original research articles, reviews, meeting abstracts, proceedings papers, book chapters, editorial material and news items; （c） year of publication： 2002-2011. Exclusion criteria： （a） articles that required manual searching or telephone access; （b） we excluded documents that were not published in the public domain; （c） we excluded a number of corrected papers from the total number of articles. MAIN OUTCOME MEASURES： （1） Type of literature; （2） annual publication output; （3） distribution according to journals; （4） distribution according to subject areas; （5） distribution according to country; （6） distribution according to institution; （7） comparison of countries that published the most papers on stem cell transplantation from different cell sources for treating Parkinson＇s disease; （8） comparison of institutions that published the most papers on stem cell transplantation from different cell sources for treating Parkinson＇s disease in the Web of Science from 2002 to 2011; （9） comparison of studies on stem cell transplantation from different cell sources for treating Parkinson＇s disease RESULTS： In total, 1 062 studies on stem cell transplantation for treating Parkinson＇s disease appeared in the Web of Science from 2002 to 2011, almost one third of which were from American authors and institutes. The number of studies on stem cell transplantation for treating Parkinson＇s disease had gradually increased over the past 10 years. Papers on stem cell transplantation for treating Parkinson＇s disease appeared in journals such as Stem Cells and Experimental Neurology. Although the United States published more articles addressing neural stem cell and embryonic stem cell transplantation for treating Parkinson＇s disease, China ranked first for articles published on bone marrow mesenchymal stem cell transplantation for treating Parkinson＇s disease. CONCLUSION： From our analysis of the literature and research trends, we found that stem cell transplantation for treating Parkinson＇s disease may offer further benefits in regenerative medicine.展开更多
Calcium antagonists are widely used in the clinical treatment of ischemic cerebrovascular disease because of their vascular and neuroprotective effects. Nimodipine, a typical calcium antagonist, can cross the blood-br...Calcium antagonists are widely used in the clinical treatment of ischemic cerebrovascular disease because of their vascular and neuroprotective effects. Nimodipine, a typical calcium antagonist, can cross the blood-brain barrier and act selectively at neurons and blood vessels of target tis-sues, thus exerting neuroprotective effects. The aim of the present study was to explore the hot spots and future trends of research on the neuroprotective effects of nimodipine. We retrieved 425 articles on the neuroprotective effects of nimodipine that were indexed in the Web of the Science database between 2000 and 2014. The retrieved articles were analyzed using document analysis reporting and the derived information function in the Web of Science, and the infor-mation visualization software CiteSpace III. The reference co-citation network was plotted, and the high frequency key words in these publications were used to analyze the research fronts and development trends for nimodipine neuroprotection. According to these co-citation clusters, the research front of nimodipine neuroprotection is the use of randomized controlled trials to study nimodipine intervention of subarachnoid hemorrhage. Using time zone view analysis on hot spots labeled with a key word, the areas of interest in the ifeld of nimodipine neuroprotection are nimodipine pharmacology and therapeutics, blood-brain barrier, trials, and anti-angiospasm.展开更多
Background Intravenous recombinant tissue plasminogen activator(r-tPA)and urokinase(UK)are both recommended for the treatment of acute ischaemic stroke(AIS)in China,but with few comparative outcome data being availabl...Background Intravenous recombinant tissue plasminogen activator(r-tPA)and urokinase(UK)are both recommended for the treatment of acute ischaemic stroke(AIS)in China,but with few comparative outcome data being available.We aimed to compare the outcomes of these two thrombolytic agents for the treatment of patients within 4.5 hours of onset of AIS in routine clinical practice in China.Methods A pre-planned,prospective,nationwide,multicentre,real-world registry of consecutive patients with AIS(age≥18 years)who received r-tPA or UK within 4.5 hours of symptom onset according to local decision-making and guideline recommendations during 2017-2019.The primary effectiveness outcome was the proportion of patients with an excellent functional outcome(defined by modified Rankin scale scores 0 to 1)at 90 days.The key safety endpoint was symptomatic intracranial haemorrhage according to standard definitions.Multivariable logistic regression was used for comparative analysis,with adjustment according to propensity scores to ensure balance in baseline characteristics.Results Overall,4130 patients with AIS were registered but 320 had incomplete or missing data,leaving 3810 with available data for analysis of whom 2666 received r-tPA(median dose 0.88(IQR 0.78-0.90)mg/kg)and 1144 received UK(1.71(1.43-2.00)×104 international unit per kilogram).There were several significant intergroup differences in patient characteristics:r-tPA patients were more educated,had less history of stroke,lower systolic blood pressure,greater neurological impairment and shorter treatment times from symptom onset than UK patients.However,in adjusted analysis,the frequency of excellent outcome(OR 1.18,95%CI 1.00 to 1.40,p=0.052)and symptomatic intracranial haemorrhage(OR 0.70,95%CI 0.33 to 1.47,p=0.344)were similar between groups.Conclusions UK may be as effective and carry a similar safety profile as r-tPA in treating mild to moderate AIS within guidelines in China.Registration http://www.clinicaltrials.gov.unique identifier:NCT02854592.展开更多
文摘OBJECTIVE： To identify global research trends of stem cell transplantation for treating Parkinson＇s disease using a bibliometric analysis of the Web of Science. DATA RETRIEVAL： We performed a bibliometric analysis of data retrievals for stem cell transplantation for treating Parkinson＇s disease from 2002 to 2011 using the Web of Science. SELECTION CRITERIA： Inclusion criteria： （a） peer-reviewed articles on stem cell transplantation for treating Parkinson＇s disease which were published and indexed in the Web of Science; （b） type of articles： original research articles, reviews, meeting abstracts, proceedings papers, book chapters, editorial material and news items; （c） year of publication： 2002-2011. Exclusion criteria： （a） articles that required manual searching or telephone access; （b） we excluded documents that were not published in the public domain; （c） we excluded a number of corrected papers from the total number of articles. MAIN OUTCOME MEASURES： （1） Type of literature; （2） annual publication output; （3） distribution according to journals; （4） distribution according to subject areas; （5） distribution according to country; （6） distribution according to institution; （7） comparison of countries that published the most papers on stem cell transplantation from different cell sources for treating Parkinson＇s disease; （8） comparison of institutions that published the most papers on stem cell transplantation from different cell sources for treating Parkinson＇s disease in the Web of Science from 2002 to 2011; （9） comparison of studies on stem cell transplantation from different cell sources for treating Parkinson＇s disease RESULTS： In total, 1 062 studies on stem cell transplantation for treating Parkinson＇s disease appeared in the Web of Science from 2002 to 2011, almost one third of which were from American authors and institutes. The number of studies on stem cell transplantation for treating Parkinson＇s disease had gradually increased over the past 10 years. Papers on stem cell transplantation for treating Parkinson＇s disease appeared in journals such as Stem Cells and Experimental Neurology. Although the United States published more articles addressing neural stem cell and embryonic stem cell transplantation for treating Parkinson＇s disease, China ranked first for articles published on bone marrow mesenchymal stem cell transplantation for treating Parkinson＇s disease. CONCLUSION： From our analysis of the literature and research trends, we found that stem cell transplantation for treating Parkinson＇s disease may offer further benefits in regenerative medicine.
基金The National Natural Science Foundation of Chinathe National Key Basic Research and Development Program(973 Program)of China sponsored 18 of the articles retrieved in our search+6 种基金The National Commission on Science and Technology Development in Brazil sponsored 6 publicationsThe Coordenao de Aperfeioamento de Pessoal de Nível Superior(the Brazilian Federal Agency for the Support and Evaluation of Graduate Education)sponsored four publicationsthe Oak Ridge Institute for Science and EducationNIH ProjectKyung Hee UniversityGerman Federal Ministry of Education and ResearchBayer Vital Gmb H Leverkusen each provided funding for two studies(Figure 5)
文摘Calcium antagonists are widely used in the clinical treatment of ischemic cerebrovascular disease because of their vascular and neuroprotective effects. Nimodipine, a typical calcium antagonist, can cross the blood-brain barrier and act selectively at neurons and blood vessels of target tis-sues, thus exerting neuroprotective effects. The aim of the present study was to explore the hot spots and future trends of research on the neuroprotective effects of nimodipine. We retrieved 425 articles on the neuroprotective effects of nimodipine that were indexed in the Web of the Science database between 2000 and 2014. The retrieved articles were analyzed using document analysis reporting and the derived information function in the Web of Science, and the infor-mation visualization software CiteSpace III. The reference co-citation network was plotted, and the high frequency key words in these publications were used to analyze the research fronts and development trends for nimodipine neuroprotection. According to these co-citation clusters, the research front of nimodipine neuroprotection is the use of randomized controlled trials to study nimodipine intervention of subarachnoid hemorrhage. Using time zone view analysis on hot spots labeled with a key word, the areas of interest in the ifeld of nimodipine neuroprotection are nimodipine pharmacology and therapeutics, blood-brain barrier, trials, and anti-angiospasm.
基金This study was funded by National Key R&D Program of China(2017YFC1308200)Stroke Prevention and Treatment Project of the National Health Commission-Research and Popularization of Appropriate Intervention Technology for the Stroke High Risk Group in China(GN-2016R0008).
文摘Background Intravenous recombinant tissue plasminogen activator(r-tPA)and urokinase(UK)are both recommended for the treatment of acute ischaemic stroke(AIS)in China,but with few comparative outcome data being available.We aimed to compare the outcomes of these two thrombolytic agents for the treatment of patients within 4.5 hours of onset of AIS in routine clinical practice in China.Methods A pre-planned,prospective,nationwide,multicentre,real-world registry of consecutive patients with AIS(age≥18 years)who received r-tPA or UK within 4.5 hours of symptom onset according to local decision-making and guideline recommendations during 2017-2019.The primary effectiveness outcome was the proportion of patients with an excellent functional outcome(defined by modified Rankin scale scores 0 to 1)at 90 days.The key safety endpoint was symptomatic intracranial haemorrhage according to standard definitions.Multivariable logistic regression was used for comparative analysis,with adjustment according to propensity scores to ensure balance in baseline characteristics.Results Overall,4130 patients with AIS were registered but 320 had incomplete or missing data,leaving 3810 with available data for analysis of whom 2666 received r-tPA(median dose 0.88(IQR 0.78-0.90)mg/kg)and 1144 received UK(1.71(1.43-2.00)×104 international unit per kilogram).There were several significant intergroup differences in patient characteristics:r-tPA patients were more educated,had less history of stroke,lower systolic blood pressure,greater neurological impairment and shorter treatment times from symptom onset than UK patients.However,in adjusted analysis,the frequency of excellent outcome(OR 1.18,95%CI 1.00 to 1.40,p=0.052)and symptomatic intracranial haemorrhage(OR 0.70,95%CI 0.33 to 1.47,p=0.344)were similar between groups.Conclusions UK may be as effective and carry a similar safety profile as r-tPA in treating mild to moderate AIS within guidelines in China.Registration http://www.clinicaltrials.gov.unique identifier:NCT02854592.
